

PODCAST

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC

K. H. J. Lim^{1,2*} & F. Gomes¹

¹Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester; ²Department of Immunology and Inflammation, Imperial College London, London, UK

Available online xxx

[Click here to listen to the Podcast](#)

In recent years, the use of therapeutic agents in patients with oncogene-addicted non-small-cell lung cancer (NSCLC) has resulted in significant and meaningful improvement in survival outcomes. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) interviews Dr Fabio Gomes (consultant medical oncologist and an expert in lung cancer) for highlights on oncogene-addicted NSCLC following the ESMO20 Virtual Congress.

Dr Gomes summarises key practice-changing studies which will inform current recommendations in this field, in particular, with updates from ADAURA and CROWN phase III clinical trials. We also deliberated on whether one should use the 'best drug' upfront. Finally, Dr Gomes discusses what not to miss in ESMO20 Asia Virtual Congress and the future outlook in the field.

Further reading:

- ADAURA: <https://www.nejm.org/doi/full/10.1056/NEJMoa2027071>
- Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. *N Engl J Med.* 2020;383:2018-2029.

FUNDING

The authors have not declared a specific grant for this particular research from any funding agency in the public, commercial or not-for-profit sectors. KHJL is currently funded by the Wellcome Imperial 4i Clinical Research Fellowship.

COMPETING INTERESTS

No competing interests in regards to this podcast. KHJL has received speaker honorarium from Janssen, outside the submitted work. FG has received speaker honorarium from AstraZeneca and Boehringer Ingelheim; grants from Takeda and Pfizer; and travel fees from Pfizer, outside the submitted work.

PATIENT CONSENT FOR PUBLICATION

Not required.

PROVENANCE AND PEER REVIEW

Not commissioned; internally peer-reviewed.

*Correspondence to: Dr Kok Haw Jonathan Lim, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. Tel: +44(0) 1614463000

E-mail: jonathan.lim@doctors.org.uk (K.H.J. Lim).

2059-7029/© 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).